Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial.
Lynda Stranix-ChibandaCamlin TierneyDorothy SebikariJim AizireSufia DadabhaiAdmire ZangaCynthia Mukwasi-KahariTichaona VhemboAvy ViolariGerard TheronDhayandre MoodleyKathleen GeorgeBo FanMarkus J SommerRenee BrowningLynne M MofensonJohn ShepherdBryan NelsonMary Glenn FowlerGeorge K Siberrynull nullPublished in: PloS one (2021)
Bone mineral density decline through week 74 postpartum was greater among breastfeeding HIV-infected women randomized to receive maternal TDF-ART during breastfeeding compared to those mothers whose infants received nevirapine prophylaxis.
Keyphrases
- bone mineral density
- antiretroviral therapy
- hiv infected
- postmenopausal women
- human immunodeficiency virus
- hiv positive
- preterm infants
- hiv infected patients
- hiv aids
- body composition
- placebo controlled
- pregnancy outcomes
- double blind
- open label
- polycystic ovary syndrome
- type diabetes
- birth weight
- adipose tissue
- pregnant women
- phase ii
- clinical trial
- physical activity
- cervical cancer screening